Subscribe
Advertise
Acuity Media Network logo
a
M&A
Technology
Regulation
|
Events
About

M

Search Our Professional Healthcare Articles...

a

// News and Events

M&A
Technology
Regulation

Events

// About Acuity Media Network

About

Advertise

Contact

Join Our Newsletter

GLP-1 Drugs for Addiction Are Moving From Anecdote to Evidence. A 2026 Trial Suggests Semaglutide Can Blunt the Urge to Drink.

GLP-1 Drugs for Addiction Are Moving From Anecdote to Evidence. A 2026 Trial Suggests Semaglutide Can Blunt the Urge to Drink.

by Ethan Webb | Jul 21, 2026 | Regulation

New trial data on GLP-1 drugs and alcohol use disorder is the strongest yet, but semaglutide remains unapproved for addiction and the questions for providers are only starting. Key Takeaways The signal is getting harder to dismiss. A 2026 randomized trial found...

Recent Posts

  • ABA Payer Relations Run on Outcomes Data, Say Magellan and CentralReach Leaders
  • New OCR Guidance Ties Medicaid Work-Requirement Exclusions to the Consent a Patient Signed at Intake
  • Georgia Medicaid ABA Enrollment Drops Its 50-Mile Residency Rule Four Months After DCH Tightened It. October Rules Trade Fixed Supervision Ratios for Audits.
  • MDMA Couples Therapy Signals a Dyadic Turn in How Psychedelic Treatment Would Be Delivered
  • New Jersey Raised Its ABA Technician Rate, but Analyst Pay Has Held Since 2020

Recent Comments

No comments to show.
Acuity Media Network Powered by eCap logo

We inform decision-makers, investors, and innovators in behavioral health through an editorially independent platform that delivers sharp insights, sparks strategic thinking, and drives measurable growth for our partners.

About Acuity Media Network

Contact Us

Editorial Standards

// Article Categories

  • M&A
  • Technology
  • Regulation
// Join Our Newsletter
// Advertise

Advertise with Acuity Media Network and reach a larger audience.

Get The Media Kit

Copyright © Acuity Media Network 2026
Privacy Policy   |   Accessibility Statement

X logo LinkedIn logo